FDA drug approval backlog increases by 15% within 6 months

Makary's departure disrupts ongoing efforts to streamline clinical trials and regulatory processes. Competing priorities among potential successors and Senate confirmation delays will hinder approvals, exacerbating existing backlogs.

Implied probability (Yes)

70%